Company Info

Pionyr Immunotherapeutics

Drug Discovery & Development

Overview

Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering, or “tuning”, the myeloid infiltrate of the tumor microenvironment with high specificity and for very specific purposes.

The company was founded in 2015 by Max Krummel, Ph.D., a professor at University of California, San Francisco School of Medicine (UCSF), who has been making significant strides in immuno-oncology since the mid-1990s. Dr. Krummel is the co-inventor of YERVOY® (ipilimumab), the first checkpoint inhibitor, which was approved in 2011 to treat melanoma. Pionyr has exclusively licensed technology from UCSF based on Dr. Krummel’s work.

In 2020, Pionyr entered a transformational alliance with Gilead Sciences (read more) ahead of receiving IND clearance for its two lead programs PY314 and PY159.

1 Contributions1 / 1

Immuno-Oncology

Tuning the Myeloid Compartment with a Best-in-Class CDMO

Kiren Khanduga; Alicia Levey, Ph.D.

Pionyr Immunotherapeutics

PAO-06-022-CL-04Jun 06, 2022

1 / 1

2 Contributors1 / 1

Kiren Khanduga

Associate Director in the CMC Group

Alicia Levey, Ph.D.

Chief Operating Officer

1 / 1